Aadi Bioscience, Inc. (NASDAQ:AADI) Short Interest Down 13.7% in January

Aadi Bioscience, Inc. (NASDAQ:AADI) was the recipient of a significant decrease in short interest in the month of January. As of January 15th, there was short interest totalling 472,700 shares, a decrease of 13.7% from the December 31st total of 547,500 shares. Approximately 2.3% of the shares of the company are short sold. Based on an average trading volume of 349,100 shares, the days-to-cover ratio is presently 1.4 days.

Hedge Funds Weigh In On Aadi Bioscience

Several hedge funds and other institutional investors have recently added to or reduced their stakes in AADI. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Aadi Bioscience in the second quarter worth about $37,000. BML Capital Management LLC purchased a new position in shares of Aadi Bioscience in the third quarter worth about $4,120,000. XTX Topco Ltd purchased a new position in shares of Aadi Bioscience in the third quarter worth about $32,000. Finally, Peapod Lane Capital LLC purchased a new position in shares of Aadi Bioscience in the fourth quarter worth about $1,397,000. 52.08% of the stock is owned by hedge funds and other institutional investors.

Aadi Bioscience Stock Performance

Shares of NASDAQ AADI opened at $2.88 on Monday. The company’s fifty day moving average price is $2.84 and its 200 day moving average price is $2.18. Aadi Bioscience has a 1 year low of $1.21 and a 1 year high of $3.81. The company has a market capitalization of $70.99 million, a PE ratio of -1.26 and a beta of 0.65.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.46) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.46). The business had revenue of $7.21 million for the quarter, compared to the consensus estimate of $6.55 million. Aadi Bioscience had a negative net margin of 246.06% and a negative return on equity of 71.87%. During the same period last year, the firm posted ($0.60) earnings per share. On average, equities analysts expect that Aadi Bioscience will post -2.04 EPS for the current year.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.